Drug Profile
Research programme: recombinant thyroid-stimulating hormone therapeutics - Trophogen
Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Trophogen
- Class Biobetters; Diagnostic agents; Pituitary gonadotropins; Radiopharmaceutical diagnostics; Thyroid hormones
- Mechanism of Action Diagnostic imaging enhancers; Thyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thyroid cancer
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Thyroid cancer (Diagnosis) in USA (unspecified route)
- 30 Aug 2023 Discontinued - Preclinical for Thyroid cancer in USA (unspecified route)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Thyroid-cancer in USA